Antihypertensive Treatment Prolongs Tissue Plasminogen Activator Door-to-Treatment Time
- 1 December 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 43 (12) , 3392-3394
Abstract
Background and Purpose—: Identifying modifiable tissue plasminogen activator treatment delays may improve stroke outcomes. We hypothesized that prethrombolytic antihypertensive treatment (AHT) may prolong door-to-treatment time (DTT). Methods—: We performed an analysis of consecutive tissue plasminogen activator–treated patients at 24 randomly selected community hospitals in the Increasing Stroke Treatment through Interventional Behavior Change Tactics (INSTINCT) trial between 2007 and 2010. DTT among stroke patients who received prethrombolytic AHT were compared with those who did not receive prethrombolytic AHT. We then calculated a propensity score for the probability of receiving prethrombolytic AHT using logistic regression with demographics, stroke risk factors, home medications, stroke severity (National Institutes of Health Stroke Scale), onset-to-door time, admission glucose, pretreatment blood pressure, emergency medical service transport, and location at time of stroke as independent variables. A paired t test was performed to compare the DTT between the propensity-matched groups. Results—: Of 534 tissue plasminogen activator–treated stroke patients analyzed, 95 received prethrombolytic AHT. In the unmatched cohort, patients who received prethrombolytic AHT had a longer DTT (mean increase, 9 minutes; 95% confidence interval, 2–16 minutes) than patients who did not. After propensity matching, patients who received prethrombolytic AHT had a longer DTT (mean increase, 10.4 minutes; 95% confidence interval, 1.9–18.8) than patients who did not receive prethrombolytic AHT. Conclusion—: Prethrombolytic AHT is associated with modest delays in DTT. This represents a potential target for quality-improvement initiatives. Further research evaluating optimum prethrombolytic hypertension management is warranted.Keywords
This publication has 9 references indexed in Scilit:
- Improving Door-to-Needle Times in Acute Ischemic StrokeStroke, 2011
- Frequency of Increased Blood Pressure Levels During Systemic Thrombolysis and Risk of Intracerebral HemorrhageStroke, 2011
- Intravenous Thrombolysis for Acute Ischaemic Stroke: Effective Blood Pressure Control MattersInternational Journal of Stroke, 2011
- Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic StrokeCirculation, 2011
- Pre–Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral HemorrhageStroke, 2009
- Aggressive Blood Pressure–Lowering Treatment Before Intravenous Tissue Plasminogen Activator Therapy in Acute Ischemic StrokeArchives of Neurology, 2008
- Time Is Brain—QuantifiedStroke, 2006
- Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trialsThe Lancet, 2004
- Hypertension and Its Treatment in the NINDS rt-PA Stroke TrialStroke, 1998